Inloggen

Login
 
Wachtwoord vergeten?

Probiodrug 2019

Volgen
 
Klik hier om dit forumtopic te volgen en automatisch op de hoogte gehouden te worden bij nieuwe berichten.
2.583 Posts, Pagina: « 1 2 3 4 5 6 ... 93 94 95 96 97 98 99 100 101 102 103 ... 126 127 128 129 130 » | Laatste
Aantal posts per pagina:  20 50 100 | Omlaag ↓
Gala-diner
0
Even wat informatie over de nieuwe CEO en CBO, waarvan ik overtuigd ben dat die van Probiodrug een succes gaan maken.
Trek je eigen conclusies, dit is slechts mijn visie.
De eerste prima resltaten onder deze nieuwe topmannen staan er al(feiten).

Ulrich Dauer – CEO Probiodrug
Dr. Ulrich Dauer has been Chief Executive Officer and Chairman of Executive Board at Probiodrug AG since May 01, 2018. He has been Chief Executive Officer and Managing Director at OMEICOS Therapeutics GmbH since April 13, 2015. Dr. Dauer served as Chief Strategy Officer of Vectura GmbH (alternative name Activaero GmbH). Dr. Dauer co-founded 4SC AG in January 1999 and served as its Chief Executive Officer from 1999 to March 31, 2013 and served as its Chairman of Management Board until March 31, 2013. Prior to that, he served as a Manager at Tripos, where he was responsible for key accounts and the acquisition of new business in Central and Eastern Europe. Before joining TRIPOS GmbH in Munich (Germany), a provider of screening libraries, software and systems integration in the life science business. He is a well-known executive in the healthcare industry as well as in the financial community. Dr. Dauer completed his Doctorate in Chemistry at the Institute of Organic Chemistry, University of Würzburg (Germany).
www.bloomberg.com/research/stocks/pri...
As one of the founders, Ulrich previously worked 14 years as CEO of 4SC AG, attracting multiple private and, upon the company's IPO in 2005, public investors. Under his leadership, 4SC closed multiple industry partnerships with international biopharmaceutical companies. In subsequent leadership positions, he executed in 2014 the €130 million trade sale of Activaero, and later took up CEO positions in a number of privately held biotech companies. Probiodrug's current CEO and co-founder of the company, Dr. Konrad Glund, has retired, but will continue to serve the company in an advisory role.
www.pharmatimes.com/appointments/prob...
Michael Schaeffer – CBO Probiodrug
Dr. Michael Schaeffer serves as Member of Executive Board at Probiodrug AG since October 01, 2018. Dr. Schaeffer serves as Chief Business Officer at Probiodrug AG since October 01, 2018. Dr. Schaeffer served as Executive Vice President of Business and Strategy at Probiodrug AG since August 2018 to October 01, 2018. Dr. Schaeffer served as Chief Executive Officer of Crelux GmbH. Dr. Schaeffer was responsible for business development, marketing and project management at Crelux. Dr. Schaeffer served as the Chief Executive Officer of Sireen AG. Dr. Schaeffer brings more than 15 years of experience across pharma and biotech in strategic business development, scientific project and alliance management to Probiodrug. He has many years research experience in the area of signal transduction and especially in hematopoietic neoplasms. Dr. Schaeffer leads his own group in the lab of Professor Hallek at the GSF. It was his initiative to integrate the research of the group and to set up a company. He received his PhD in Molecular Biology from Ludwig-Maximilians-Universität in Munich, Germany.
Dr. Schaeffer brings more than 15 years of experience across pharma and biotech in strategic business development, scientific project and alliance management to Probiodrug.


Gala-diner
0
De super-goeroe’s over Avantium, koers nu €2,755…

DeZwarteRidder 18 jan 2019 om 15:24

Binnenkort staat dit aandeel op 1,50 of lager en binnen een jaar is het een pennystock.
Stephan010 18 jan 2019 om 11:10

Emissie op bijna €2,- ?
Dan gaat koers naar pennystock (zonder emissie ook een pennystock waardig aandeel). Zoals ik al eerder schreef koers gaat omlaag zoals vandaag weer -3%..

Ja, dit zijn de mannen die je moet volgen om winst mis te lopen. Geniaal…

Gala-diner
0
Whereas QPCTL has been identified as a potential target in cancer therapy. Blocking the enzymatic function of QPTCL by small molecule inhibitors is a novel therapeutic approach in cancer immunotherapy. Probiodrug has a unique and exceptionally strong patent position on QPCT and QPCTL inhibitors.
Glutaminyl-peptide cyclotransferase-like protein (QPCTL)
Glutaminyl-peptide cyclotransferase-like protein (QPCTL) is a posttranslational modifying enzyme that is responsible for the pyroglutamate formation on crucial proteins in the immune response to cancer.

Cancer immune checkpoint inhibitors
Checkpoint inhibitor therapy is a novel kind of cancer immunotherapy. The therapy targets immune checkpoints, key regulators of the immune system that stimulate or inhibit its actions, which tumors can use to protect themselves from attacks by the immune system. QPCTL inhibitor therapy can block inhibitory cancer checkpoints and thereby restore beneficial immune system functions.
[verwijderd]
0
Gala, een welgemeend advies: ga eens van het mooie weer genieten en laat PBD en vooral DZR eens even "los". :-) Dauer en Schaeffer zitten nu ongetwijfeld ergens in de zon, misschien wel in Zeeland tussen vele landgenoten. Volgende week dinsdag gaat het PBD-circus weer verder en kun je doorgaan met promoten.
DeZwarteRidder
0
quote:

Gala-diner schreef op 19 apr 2019 om 14:52:


Even wat informatie over de nieuwe CEO en CBO, waarvan ik overtuigd ben dat die van Probiodrug een succes gaan maken.
Trek je eigen conclusies, dit is slechts mijn visie.
De eerste prima resltaten onder deze nieuwe topmannen staan er al(feiten).

Ulrich Dauer – CEO Probiodrug
Dr. Ulrich Dauer has been Chief Executive Officer and Chairman of Executive Board at Probiodrug AG since May 01, 2018. He has been Chief Executive Officer and Managing Director at OMEICOS Therapeutics GmbH since April 13, 2015. Dr. Dauer served as Chief Strategy Officer of Vectura GmbH (alternative name Activaero GmbH). Dr. Dauer co-founded 4SC AG in January 1999 and served as its Chief Executive Officer from 1999 to March 31, 2013 and served as its Chairman of Management Board until March 31, 2013. Prior to that, he served as a Manager at Tripos, where he was responsible for key accounts and the acquisition of new business in Central and Eastern Europe. Before joining TRIPOS GmbH in Munich (Germany), a provider of screening libraries, software and systems integration in the life science business. He is a well-known executive in the healthcare industry as well as in the financial community. Dr. Dauer completed his Doctorate in Chemistry at the Institute of Organic Chemistry, University of Würzburg (Germany).
www.bloomberg.com/research/stocks/pri...
As one of the founders, Ulrich previously worked 14 years as CEO of 4SC AG, attracting multiple private and, upon the company's IPO in 2005, public investors. Under his leadership, 4SC closed multiple industry partnerships with international biopharmaceutical companies. In subsequent leadership positions, he executed in 2014 the €130 million trade sale of Activaero, and later took up CEO positions in a number of privately held biotech companies. Probiodrug's current CEO and co-founder of the company, Dr. Konrad Glund, has retired, but will continue to serve the company in an advisory role.
www.pharmatimes.com/appointments/prob...
Michael Schaeffer – CBO Probiodrug
Dr. Michael Schaeffer serves as Member of Executive Board at Probiodrug AG since October 01, 2018. Dr. Schaeffer serves as Chief Business Officer at Probiodrug AG since October 01, 2018. Dr. Schaeffer served as Executive Vice President of Business and Strategy at Probiodrug AG since August 2018 to October 01, 2018. Dr. Schaeffer served as Chief Executive Officer of Crelux GmbH. Dr. Schaeffer was responsible for business development, marketing and project management at Crelux. Dr. Schaeffer served as the Chief Executive Officer of Sireen AG. Dr. Schaeffer brings more than 15 years of experience across pharma and biotech in strategic business development, scientific project and alliance management to Probiodrug. He has many years research experience in the area of signal transduction and especially in hematopoietic neoplasms. Dr. Schaeffer leads his own group in the lab of Professor Hallek at the GSF. It was his initiative to integrate the research of the group and to set up a company. He received his PhD in Molecular Biology from Ludwig-Maximilians-Universität in Munich, Germany.
Dr. Schaeffer brings more than 15 years of experience across pharma and biotech in strategic business development, scientific project and alliance management to Probiodrug.

Het zijn typische uitzendkrachten die voor iedereen willen werken voor het juiste salaris.
[verwijderd]
0
Gala-diner
0
Probiodrug AG
Halle (Saale), Germany
Handelsregister: Amtsgericht Stendal, HRB 213719
(Commercial Register: Local Court of Stendal, HRB 213719)
ISIN: DE0007921835
Notification and public disclosure of transactions by persons discharging managerial responsibilities
and persons closely associated with them
1. Details of the person discharging managerial responsibilities / person closely associated
a) Name
Name and legal form: PlatzerInvest AG
2. Reason for the notification
a) Position / status
Person closely associated with:
Title:
First name: Erich
Last name(s): Platzer, MD
Position:
Member of the administrative or supervisory
body
b) Initial notification
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or
auction monitor
a) Name
Probiodrug AG
b) LEI
3912004AMB0KGZXZYJ15
4. Details of the transaction(s)
a) Description of the financial instrument, type of instrument, identification code
Type: Share
ISIN: DE0007921835
b) Nature of the transaction
Acquisition in the frame of a capital increase utilizing authorized capital
c) Price(s) and volume(s)
Price(s) Volume(s)
2.00 EUR 102000.00 EUR
d) Aggregated information
Gala-diner
0
Probiodrug AG
Halle (Saale), Germany
Handelsregister: Amtsgericht Stendal, HRB 213719
(Commercial Register: Local Court of Stendal, HRB 213719)
ISIN: DE000A2TSH69
Notification and public disclosure of transactions by persons discharging managerial responsibilities
and persons closely associated with them
1. Details of the person discharging managerial responsibilities / person closely associated
a) Name
Title: Dr.
First name: Ulrich
Last name(s): Dauer
2. Reason for the notification
a) Position / status
Position: Member of the managing body
b) Initial notification
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or
auction monitor
a) Name
Probiodrug AG
b) LEI
3912004AMB0KGZXZYJ15
4. Details of the transaction(s)
a) Description of the financial instrument, type of instrument, identification code
Type: Share
ISIN: DE000A2TSH69
b) Nature of the transaction
Acquisition in the frame of a capital increase utilizing authorized capital
c) Price(s) and volume(s)
Price(s) Volume(s)
2.00 EUR 50000.00 EUR
d) Aggregated information
Price Aggregated volume
2.00 EUR 50000.00 EUR
DeZwarteRidder
0
T&W Holding A/S - Probiodrug AG - Halle

Hieronder vindt u informatie uit het register substantiële deelnemingen en bruto shortposities. Deze informatie is door de organisatie verstrekt.

Datum meldingsplicht 18 apr 2019
Meldingsplichtige T&W Holding A/S
Uitgevende instelling Probiodrug AG
Plaats Halle

Vorige register resultaat
Volgende register resultaat
Verdeling in aantallen (longpositie)
Soort aandeel Aantal aandelen Aantal stemmen Kapitaalbelang Stemrecht Wijze van beschikken Afwikkeling
Gewoon aandeel 1.000.000,00 1.000.000,00 Reëel Reëel Rechtstreeks In contanten
Procentuele verdeling (longpositie)
Soort aandeel Totale deelneming Rechtstreeks reëel Rechtstreeks potentieel Middellijk reëel Middellijk potentieel
Kapitaalbelang 8,13 % 8,13 % 0,00 % 0,00 % 0,00 %
Stemrecht 8,13 % 8,13 % 0,00 % 0,00 % 0,00 %

Datum laatste update: 24 april 2019
Gala-diner
0
quote:

Bones schreef op 24 apr 2019 om 13:56:


Saai

Zo kunnen de ongeduldigen er rustig uit stappen, die komen dan weer snel terug als het boven de €6 staat of wanneer er een samenwerking gemeld wordt :-)
Tis lekker weer, geniet er van.
Gala-diner
0
quote:

Bones schreef op 24 apr 2019 om 14:23:


Lig op het terras met de ipad op de 4 euro te wachten ;)

Doe gerust je ogen dicht, de €4 gaat er niet meer komen.
[verwijderd]
0
Alex69
0
Ik moet zeggen dat Probio behoorlijk goed blijft liggen en dat de correctie na de enorme stijging vanaf 1.40 tot dusver beperkt is. Intraday hebben we een keer 4,53 gezien volgens mij maar daar staan we nog ruim boven. Ik ben benieuwd of de daling morgen nog doorzet of dat we weer een stijgende lijn gaan zien. Het volume droogt langzaam wel wat op (wat m.i. een positief signaal is bij een daling)
2.583 Posts, Pagina: « 1 2 3 4 5 6 ... 93 94 95 96 97 98 99 100 101 102 103 ... 126 127 128 129 130 » | Laatste
Aantal posts per pagina:  20 50 100 | Omhoog ↑

Plaats een reactie

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord

Direct naar Forum

Probiodrug Meer »

Koers 5,540   Verschil -0,05 (-0,89%)
Laag 5,540   Volume 1.031
Hoog 5,600   Gem. Volume 17.817
24-jun-19 09:25
label premium

Probiodrug: Bodem van de kas in zicht

Het laatste advies leest u als IEX Premium-lid

Inloggen Ontdek Premium

Gerelateerde Video's